Roxithromycin 300 MG
DrugRoxithromycin 300 mg oral per day
Other names: Roxithromycin
NCT Number: NCT04122040
roxithormycin 300 mg per day for 12 weeks could improve quality of life and physiological outcomes in bronchiectasis
Looking for future studies?
Notify Me18 year–70 year
All sexes
Interventional
Phase 3
A randomized, double blinded, placebo controlled study was conducted to evaluate the effects of a 12-week administration of roxithromycin 300 mg once daily and a 12-week follow-up period in symptomatic stable bronchiectasis
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
minimum 15 year maximum 75 years
Criteria inclusion Criteria:
Symptomatic bronchiectasis Stable clinical bronchiectasis
Exclusion criteria
Adverse drug reaction to macrolide Recent exacerbation within 2 weeks History of macrolide therapy within 2 weeks active malignancy and end stage diseases 5. not perform lung function tests Females who were lactating
Roxithromycin 300 mg oral per day
Other names: Roxithromycin
Placebo one table oral once dialy
Time frame: for 12 weeks
SGRQ scores
Time frame: 24 weeks
FEV1
Time frame: 24 wekse
sputum volume per day
Prince of Songkla University
Other
Effects of Roxithromycin on Quality of Life and Physiologic Outcomes in Bronchiectasis Patients During Treatment and Posttreatment Period
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06820983
Bronchial Diseases, Bronchiectasis
Amiens, France
View Trial DetailsNCT06750692
Brain Diseases, Cardiovascular Diseases
Afyonkarahisar, Turkey (Türkiye)
View Trial DetailsNCT07720752
Behavior, Climate Change Anxiety
Islamabad, Pakistan
View Trial DetailsNCT06654869
Cancer, Neoplasms
Erzurum, Yakutiye, Turkey (Türkiye)
View Trial Details